The Japan Kidney Association and Renalys Pharma Form Collaborative Agreement to overcome kidney disease
The Japan Kidney Association, a nonprofit organization, (Headquarters: Bunkyo-ku, Tokyo; “Japan Kidney Association”) and Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys Pharma”) entered into a collaborative agreement on May 1, 2024, with the aim to develop innovative therapies and raise the awareness to overcome kidney disease. “Kidney disease is increasing against a background of changing […]
Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO
～Hidemasa’s appointment bolsters Aculys’ position as a leader in the field of CNS in Japan and Asia～ Aculys Pharma, Inc. (“Aculys”), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announces the appointment of Hidemasa Tanigaki as Chief Executive Officer and Representative Director, effective March 29th. Hidemasa has an outstanding track […]
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Aculys Pharma receives orphan drug designation for a diazepam nasal spray: an antiepileptic drug for epileptic seizures
Tokyo, Japan, November 24, 2023 — Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announced that a diazepam nasal spray (compound development code: NRL-1), an antiepileptic drug currently under development for the treatment of epileptic seizures, has been designated as an orphan drug by the Ministry of Health, Labour […]
Aculys Pharma Announces Leadership Change
Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announced that Kazunari Tsunaba will be leaving his position as Chief Executive Officer. Takeshi Takahashi, a co-founder, and a member of the Board will be acting as interim Chief Executive Officer effective immediately. Mr. Takahashi will lead […]
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
• Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position.• Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and commercial milestone payments in addition to tiered […]
Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
These results are from Japan’s first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients aged 6 to 17 for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus. The primary efficacy endpoint was met in a pre-specified interim analysis, and the drug was found […]
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Aculys Pharma and Medical Note enter into a partnership to raise awareness on sleep disorders
Goal to build a “sleep ecosystem” to resolve sleep-related social issues in Japan, which cause an economic loss of approximately 15 trillion yen annually Tokyo, Japan, May 23, 2023 – Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, and MedicalNote, Inc. (“Medical Note”), a leading online healthcare […]
Aculys Pharma joins the Sleep Services Consortium of Japan
As a venture to establish a new pharmaceutical model,supports the efforts to address sleep issues across industry boundaries. Tokyo, Japan, March2, 2023 — Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions announced today that it joined the Sleep Services Consortium. The Consortium is Japan’s organization bringing together […]